S
BIOR

Surevest’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Surevest’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 608
2022
Q2 		$0 Hold
1
– – ﹤0.01% 609
2022
Q1 		$0 Hold
1
– – ﹤0.01% 576
2021
Q4 		$0 Buy
+1
New +$718 ﹤0.01% 554

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Surevest's BIOR Position: Q3 2022 in Review

Surevest sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q3 2022, closing a stake of 1 share.

Surevest first reported a position in BIOR in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q2 2022. 44 funds tracked by Wall St. Rank hold BIOR as of Q3 2022.

  • Surevest reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Surevest sold 1 Biora Therapeutics, Inc. Common Stock share in Q3 2022.
  • Surevest first reported a position in Biora Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Surevest's Biora Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 44 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Surevest's 13F filing for Q3 2022, filed 14 Nov 2022.